Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.

Young-Suk LimWai Kay SetoMasayuki KurosakiScott FungJia-Horng Kao Jinlin HouStuart C GordonJohn F FlahertyLeland J YeeYang ZhaoKosh AgarwalPietro Lampertico

Published in: Alimentary pharmacology & therapeutics (2022)

Switching to TAF appears to maintain or improve virological, biochemical and bone- and renal-related safety outcomes. These data support the concept of switching to TAF in some patients with CHB based on their individual circumstances.

Keyphrases

electronic health record
big data
antiretroviral therapy
hepatitis b virus
bone mineral density
bone loss
insulin resistance
body composition